Compositions and methods for treating cancer
AssigneeCedars-Sinai Medical Center
InventorsMichael FREEMAN, Mirja ROTINEN, Ramachandran MURALI, Sungyong YOU
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject.
Claims21
1-46. (canceled)
A method for treating, inhibiting, or reducing the severity of cancer that overexpress ONECUT2 in a subject in need thereof, comprising:
- providing an agent that inhibits expression or activity of ONECUT2;
- and administering a therapeutically effective amount of the agent so as to treat, inhibit, or reduce the severity of cancer that overexpress ONECUT2 in the subject.
A compound of Formula I, Formula II, Formula III, Formula IV, or Formula V, wherein:
- a) the compound of Formula I has the structure:
- wherein:
- n is 0, 1, 2, 3, 4 or 5;
- X is NHC(O), C(O)NH, OC(O), C(O)O, C(O), or CH═N;
- Y is alkyl, heteroalkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted;
- and any pharmaceutically acceptable salt thereof, provided that the compound is not
- b) the compound of Formula II has the structure:
- wherein:
- n is 0, 1, 2, 3, 4 or 5;
- X is NHC(O), C(O)NH, OC(O), C(O)O, or C(O);
- Y is alkyl, heteroalkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted;
- and any pharmaceutically acceptable salt thereof;
- c) the compound of Formula III has the structure:
- wherein:
- X is NH, or O;
- Y is alkyl, heteroalkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted;
- and any pharmaceutically acceptable salt thereof;
- d) the compound of Formula IV has the structure:
- wherein:
- X is C(O), C(O)(CH2)mO, or C(O)(CH2)mNH;
- Y is alkyl, heteroalkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted;
- m is 0, 1, 2, 3, 4, or 5;
- R is H, CH3, alkyl, NH2, or OR′, where R′ is H, CH3, or alkyl;
- and any pharmaceutically acceptable salt thereof;
- and
- e) the compound of Formula V has the structure:
- wherein:
- Y is alkyl, heteroalkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted;
- and any pharmaceutically acceptable salt thereof.
A compound selected from:
Dependencies are inferred from the claim text.